A Report of Rabbit Syndrome who Benefited from Sigma 1 Agonist Fluvoxamine
Yakup Albayrak *, Murat Beyazyüz , Özlem Abbak , Ece Altındağ
Namık Kemal University, School of Medicine
Received: March 16, 2017; Revised: July 13, 2017; Accepted: July 19, 2017; Published online: July 19, 2017.
© The Korean College of Neuropsychopharmacology. All rights reserved.

Abstract
Rabbit Syndrome is an uncommon side effect of antipsychotic treatment. Although it is usually associated with typical antipsychotics, it can also be related to atypical antipsychotics. Anticholinergics are the most accepted treatment approach in treating Rabbit Syndrome. Fluvoxamine is a member of selective serotonin re-uptake inhibitors and it is a potent agonist of sigma 1 receptors. In this article, we report a Rabbit Syndrome case who has benefited from fluvoxamine, in terms of both depressive disorder and Rabbit Syndrome; and present the data on the effects of sigma 1 agonist fluvoxamine on numerous movement disorders.
Keywords: Rabbit Syndrome, sigma receptor, agonist, fluvoxamine


e-submission

Archives